ID,Abstract Title,Primary Drug,Secondary Drug,Comparator Drug,
1,Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry,Axicabtagene Ciloleucel,,Lisocabtagene Maraleucel,
2,Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO,"GemOx, Glofitamab",,"GemOx, Rituximab",
3,"Real-world effectiveness of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) among elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL) in the United States","Polatuzumab Vedotin, R-CHP",,R-CHOP,
4,Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma,"Mosunetuzumab, Polatuzumab Vedotin",,"Polatuzumab Vedotin, Rituximab",
5,Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups,Gemox,,R-Gemox,
6,Zilovertamab vedotin plus R-CHP versus R-CHOP for first-line treatment of diffuse large B-cell lymphoma: The phase 3 waveline-010 study,"R-Chp, Zilovertamab Vedotin",,RCHOP,
7,"Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in participants with germinal center B-cell diffuse large B-cell lymphoma (DLBCL): The randomized, open-label, Phase 2 waveline-011 Study","R-Chp, Zilovertamab Vedotin",,"Polatuzumab Vedotin, R-Chp",
8,"SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma","Rituximab, Surovatamig",,Rituximab,
9,"Treatment inequities in newly diagnosed diffuse large B-cell lymphoma (DLBCL): Comparing polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) vs rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) among Medicare beneficiaries",Pola-R-CHP,,R-CHOP,
10,"Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy","Mosunetuzumab, Polatuzumab Vedotin",,"Gemcitabine, Oxaliplatin, Rituximab",
11,"A prospective, multicenter, randomized, controlled clinical trial comparing polatuzumab vedotin, zanubrutinib, lenalidomide, and rituximab (Pola-ZR2) versus zanubrutinib, lenalidomide, and rituximab (ZR2) in the treatment of previously untreated, elderly patients with diffuse large B-cell lymphoma (NCT06522555)","Lenalidomide, Polatuzumab Vedotin, Rituximab, Zanubrutinib",,"Lenalidomide, Rituximab, Zanubrutinib",
12,"Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola R+CHP) results in similar clinical outcomes than rituximab and dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R+DA-EPOCH) in patients with high-risk features diffuse large B-cell lymphoma (DLBCL): A single institution experience.",Pola R-CHP,,R-DA-EPOCH,
13,Comparative safety and effectiveness of apixaban versus warfarin in antiphospholipid syndrome with chronic kidney disease: A real-world propensity-matched cohort study,Apixaban,,Warfarin,
14,Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed/Refractory multiple myeloma,"Belantamab Mafodotin, Bortezomib, Dexamethasone",,"Bortezomib, Daratumumab, Dexamethasone",
15,Outcomes of elderly patients with newly diagnosed multiple myeloma (NDMM): A retrospective comparison of daratumumab-based induction versus autologous stem cell transplant (autoSCT),Daratumumab,,Autologous Stem Cell Transplant,
16,Comparative effectiveness and safety of apixaban vs. rivaroxaban in patients with cirrhosis and portal vein thrombosis: An analysis of real-world data,Apixaban,,Rivaroxaban,
17,Comparative effectiveness of R-minichop versus R-CHOP in older patients with diffuse large B-cell lymphoma: A propensity score-matched analysis from a real-world grupo de estudio latinoamericano de linfoproliferativos (GELL) cohort,R-Minichop,,R-Chop,
18,Longer survival with tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a real-world analysis,Tagraxofusp,,Venetoclax,
19,A retrospective analysis of outcomes of high-risk myelodysplastic syndrome patients treated with upfront decitabine/cedazuridine versus hypomethylating agents with venetoclax utilizing real-world data,"Cedazuridine, Decitabine",,Venetoclax,
20,Risk of serious bleeding with concomitant use of apixaban or rivaroxaban with amiodarone compared to flecainide or sotalol in patients with atrial fibrillation,"Amiodarone, Apixaban, Rivaroxaban",,Flecainide,
21,"Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis",Autologous Stem Cell,,CD19 CAR-T Cell,
22,"Randomized comparison between isatuximab-rd versus rd induction, followed by isa-R versus R maintenance in very elderly patients with NDMM: Efficacy data on MRD after induction (AGMT-MM04 Trial)","Dexamethasone, Isatuximab, Lenalidomide",,"Dexamethasone, Isatuximab, Lenalidomide",
23,"Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study","Daratumumab, Dexamethasone, Ixazomib",,"Daratumumab, DVD",
24,"Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) - the FRAIL-m study (AMaRC 19-01; ALLG MM22)",Bortezomib,,Lenalidomide,
25,Comparative outcomes of posaconazole vs. voriconazole/isavuconazole for antifungal prophylaxis in neutropenic adults with Acute Myeloid Leukemia: A propensity-matched retrospective cohort study,Posaconazole,,"Isavuconazole, Voriconazole",
26,Randomized comparison of ponatinib versus imatinib in combination with chemotherapy in patients 55 years of age and older with newly diagnosed ph+ ALL: Molecular response and initial outcome analysis of the EWALL PH03 Study,Ponatinib,,Imatinib,
27,"Incidence of cardiac toxicities in patients with hematologic malignancies treated with zanubrutinib compared to control, including BTK inhibitor (Ibrutinib): A meta-analysis of randomized controlled trials",Zanubrutinib,,Ibrutinib,
28,Progression-free survival in patients with low health-related quality of life treated with zanubrutinib versus ibrutinib monotherapy: Post hoc analysis of the ALPINE trial,Zanubrutinib,,Ibrutinib,
29,"A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)",Sonrotoclax,,Venetoclax,
30,Cyclophosphamide versus methotrexate for treating large granular lymphocyte leukemia: Real-world data insights,Cyclophosphamide,,Methotrexate,
31,"A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma","Daratumumab, Etentamig",,"Daratumumab, Dexamethasone, Lenalidomide",
32,"CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma",BGB-16673,,Pirtobrutinib,
33,Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis,Hyper-Cvad,,"Blinatumomab, Hyper-Cvad",
34,"Trial in progress: A phase 3, multi-regional, open-label, randomized study of tirabrutinib vs rituximab and temozolomide in participants with Relapsed/Refractory primary central nervous system lymphoma",Tirabrutinib,,"Rituximab, Temozolomide",
35,"MagnetisMM-6 part 2: A phase 3, open-label, randomized study of elranatamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma","Daratumumab, Elranatamab, Lenalidomide",,"Daratumumab, Dexamethasone, Lenalidomide",
36,"Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoDT agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma","Golcadomide, R-Chop",,R-Chop,
37,Comparative effectiveness of CAR-T cell therapy vs. teclistamab in relapsed/refractory multiple myeloma: A real-world propensity-matched analysis revealing survival advantages and treatment disparities,Car-T Cell,,Teclistamab,
38,Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis,"AVD, Brentuximab Vedotin",,ABVD,
39,Blinatumomab and ponatinib vs. hyper-CVAD and ponatinib in patients with Philadelphia-chromosome positive acute lymphoblastic leukemia: A propensity score analysis,"Blinatumomab, Ponatinib",,"Hyper-Cvad, Ponatinib",
40,"MRD-guided ibrutinib plus venetoclax improves outcomes in CLL patients with TP53, ATM, or NOTCH1 aberrations compared to ibrutinib and FCR: Results from the Phase III NCRI FLAIR trial","Ibrutinib, Venetoclax",,Ibrutinib,
41,Real-world comparative outcomes of pola-R-CHP versus R-CHOP in patients with diffuse large B-cell lymphoma,Pola-R-Chp,,R-Chop,
42,Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study,Zanubrutinib,,"Bendamustine, Rituximab",
43,Acalabrutinib monotherapy versus acalabrutinib plus obinutuzumab combination therapy in treatment-naïve chronic lymphocytic leukemia: A ‘real-world’ study of efficacy and safety at a tertiary academic medical center,Acalabrutinib,,"Acalabrutinib, Obinutuzumab",
44,Evaluation of a newly formulated intranasal desmopressin versus intranasal and subcutaneous desmopressin in individuals with type 1 von Willebrand disease and mild Hemophilia A,Desmopressin,,Desmopressin,
45,"A multicenter, randomized, open-label study of dexamethasone versus romiplostim plus dexamethasone as first line treatment in patients with newly diagnosed immune thrombocytopenia: Interim results of rodex study",Dexamethasone,,"Dexamethasone, Romiplostim",
46,Real-world treatment patterns & outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the real-AVA 3.5 study,Avatrombopag,,"Eltrombopag, Romiplostim",
47,CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party,Car T-Cell,,Autologous Hematopoietic Stem Cell,
48,Real-world comparative outcomes of CAR-T cell therapy versus pomalidomide-based regimens in relapsed/refractory multiple myeloma: A propensity-matched cohort study,CAR-T Cell,,Pomalidomide,
49,"Real world evidence comparing idecabtagene vicleucel (Ide-cel, Abecma) versus ciltacabtagene autoleucel (Cilta-cel, Carvykti) chimeric antigen receptor T-cell (CART) therapy among patients with Relapsed/Refractory multiple myeloma (RRMM)",Idecabtagene Vicleucel,,Ciltacabtagene Autoleucel,
50,Longitudinal assessments of minimal residual disease in high-risk patients from benefit phase 3 randomized Study of isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isard in newly diagnosed transplant ineligible multiple myeloma. (IFM 2020-05),Isa-VRd,,ISARD,
51,Axicabtagene ciloleucel versus tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma,Axicabtagene Ciloleucel,,Tisagenlecleucel,
52,Acalabrutinib vs zanubrutinib as first-line therapy in CLL: A propensity score-matched study,Acalabrutinib,,Zanubrutinib,
53,Propensity score matched comparison of outcomes following treatment with pola-R-CHP versus R-CHOP for diffuse large B cell lymphoma patients captured in a real-world database,Pola-R-Chp,,R-Chop,
54,Short-term outcomes of rituximab versus thrombopoietin receptor agonists in Myelodysplastic Syndromes: A 90-day propensity-matched analysis using real-world data,Rituximab,,Thrombopoietin,
55,A comparison of overall survival and quality of life in MDS patients treated with azacytidine vs decitabine: A propensity matched registry Study,Azacytidine,,Decitabine,
56,Comparative safety and efficacy of bendamustine versus fludarabine/cyclophosphamide prior to chimeric antigen receptor- T cell therapy: A systematic review and meta-analysis,Bendamustine,,"Cyclophosphamide, Fludarabine",
57,Efficacy and safety of pozelimab plus cemdisiran versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria who received prior C5 therapy,"Cemdisiran, Pozelimab",,Ravulizumab,
58,"Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients",Flonoltinib Maleate,,Ruxolitinib,
59,Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective multicenter phase II trial,Ruxolitinib,,Allogeneic Stem Cell,
60,Comparative risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag versus romiplostim: A target trial emulation in the french adult immune thrombocytopenia (FAITH) cohort,Eltrombopag,,Romiplostim,
61,Ruxolitinib and interferon alfa induce superior rates of complete peripheral blood count remission compared to anagrelide in hydroxyurea-exposed essential thrombocythemia,"Interferon Alfa, Ruxolitinib",,Anagrelide,
62,PET-adaptive beacopp- versus ABVD-based therapies for advanced-stage (AS) classic Hodgkin lymphoma (cHL): Survival comparisons leveraging a multi-state model and analyzing the impact of a-hipi scores across the disease course,Beacopp,,Abvd,
63,Frontline nilotinib vs dasatinib in newly diagnosed chronic phase chronic myeloid leukemia: A propensity score analysis based on AIFA monitoring registries,Nilotinib,,Dasatinib,
64,Siltuximab versus tocilizumab for the management of CAR T-cell associated cytokine release syndrome,Siltuximab,,Tocilizumab,
65,Prospera (ABNL-MARRO 002): A randomized phase 2 study of pacritinib vs. hydroxyurea in patients with advanced proliferative chronic myelomonocytic leukemia (CMML),Pacritinib,,Hydroxyurea,
66,"Early Results of comparison of low-dose generic dasatinib (50 MG/Day) versus imatinib (400 MG/Day) in newly diagnosed chronic Phase chronic myeloid leukemia: Real-world evidence from a single-center, randomized controlled study from India",Dasatinib,,Imatinib,
67,Efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF for stem cell mobilization and collection in multiple myeloma: A single-center comparative analysis and interim Results from a prospective study in poor mobilizers,"G-CSF, Motixafortide",,"G-Csf, Plerixafor",
68,MRD-guided outcome analysis of ponatinib plus hyper-CVAD versus historical imatinib in ph-positive ALL: Impact of early response and dose-adjusted ponatinib,"Hyper-Cvad, Ponatinib",,Ponatinib,
69,Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL,Orca-T Allogeneic CAR19/22,,Autologous CAR19/22,
70,Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma,Zanubrutinib,,Ibrutinib,
71,EZH2 and CREBBP mutation status identify a subset of patients who benefit from bendamustine- over CHOP/CVP-based immunochemotherapies in follicular lymphoma: Findings from the GALLIUM trial and validation in a large international cohort,Bendamustine,,"CHOP, CVP",
72,"International, prospective study comparing nilotinib versus imatinib with early switch to nilotinib to obtain sustained treatment-free remission (TFR) in patients with chronic myeloid leukemia: The tfr rate at the end of follow-up",Nilotinib,,"Imatinib, Nilotinib",
73,Outcomes of elderly (? 70) Acute Myeloid Leukemia (AML) patients receiving continued hypomethylating agent/venetoclax (HMA/VEN) versus allogeneic hematopoietic cell transplantation (HCT),Venetoclax,,Allogeneic Hematopoietic Cell,
74,Inotuzumab ozogamicin vs blinatumomab bridging optimization and second CD19 CAR-T efficacy in Relapsed/Refractory B-ALL,Inotuzumab Ozogamicin,,Blinatumomab,
75,Bortezomib-melphalan-prednisone (VMP) +/- daratumumab (DVMP) vs. lenalidomide-dexamethasone (Rd) +/- daratumumab (DRd) in transplant-ineligible real-life multiple myeloma patients: Results from the randomized phase IV real MM trial,"Bortezomib, Melphalan, Prednisone",Daratumumab,"Daratumumab, Lenalidomide/Dexamethasone",
76,Population differences and comparative efficacy between ciltacabtagene autoleucel (cilta-cel) from the cartitude-1 study and anitocabtagene autoleucel (anito-cel) from the iMMagine-1 study in patients with relapsed / refractory multiple myeloma (RRMM),Ciltacabtagene Autoleucel,,Anitocabtagene Autoleucel,
77,"Orelabrutinib plus bendamustine-rituximab (OBR) Versus Bendamustine-rituximab (BR) in transplant-ineligible, intermediate- to high-risk Mantle Cell Lymphoma (MCL)","Bendamustine, Orelabrutinib, Rituximab",,"Bendamustine, Rituximab",
78,"Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)","Azacitidine, Venetoclax",,Azacitidine,
79,Comparison of autologous HCT versus haploidentical donor HCT for Ph+ B-ALL patients following TKI therapy. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation,Autologous Hematopoietic Stem Cell,,Haploidentical Donor Hematopoietic Stem Cell,
80,An open label randomized Study of low dose dasatinib (50 mg OD) vs standard dose dasatinib (100 mg OD) vs standard dose imatinib (400 mg OD) as upfront therapy in patients with newly diagnosed chronic myeloid leukemia (CML) - chronic Phase (CP),Dasatinib,,"Dasatinib, Imatinib",
81,A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03),"ASTX-727, Venetoclax",,Enasidenib,
82,Orca-T demonstrates favorable quality of life and healthcare resource use compared to standard allohsct plus tac/MTX for GVHD prevention in a randomized Phase 3 clinical trial (Precision-T),Orca-T,,"Allogeneic Hematopoietic Stem Cell, Methotrexate, Tacrolimus",
83,Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors,Orca-T,,Cyclophosphamide,
84,Flumatinib versus nilotinib as first-line therapy for chronic myeloid leukemia in chronic Phase: A propensity score-matched cohort study,Flumatinib,,Nilotinib,
85,Topical cyclosporine vs tacrolimus for ocular GVHD prophylaxis after outpatient allogeneic hematopoietic stem cell transplantation: A Phase I-II trial,Cyclosporine,,Tacrolimus,
86,Comparison of 80 mg/kg vs. 100 mg/kg post-transplant cyclophosphamide dose with flu/mel and allogeneic transplant: Less is not more,Cyclophosphamide,,"Allogeneic Stem Cell, Fludarabine, Melphalan",
87,Trial in progress: Efficacy and safety of givinostat versus hydroxyurea in patients with polycythemia vera (GIV-IN-PV),Givinostat,,Hydroxyurea,
88,"Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation",Cyclophosphamide,,Tacrolimus/Methotrexate,
89,"A randomized phase 2 trial of CPX-351 vs. CLAG-m (Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone) in medically less-fit adults with previously untreated acute myeloid leukemia (AML) or other high-grade myeloid neoplasms",CPX-351,,"Cladribine, Cytarabine, G-Csf, Mitoxantrone",
90,"Comparing CHOP, R-CHOP, R-EPOCH, and DA-EPOCH-R in HIV-associated diffuse large B-cell lymphoma: A meta-analysis and systematic review",CHOP,,"Da-Epoch-R, R-Chop, R-Epoch",
91,Comparable remission rates in therapy-related and myelodysplasia-related Acute Myeloid Leukemia (AML) versus de novo AML treated with azacitidine and venetoclax: A contemporary real-world study.,"Azacitidine, Venetoclax",,"Azacitidine, Venetoclax",
92,A retrospective survival outcomes analysis of acute erythroid leukemia patients treated with upfront 7+3 induction chemotherapy versus hypomethylating agents with venetoclax utilizing real-world data,7+3,,Venetoclax,
93,Incidence of heart failure in patients with acute myeloid leukemia who received daunorubicin versus idarubicin: An analysis of the trinetx database,Daunorubicin,,Idarubicin,
94,CPX-351 versus venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia: A comparative analysis of outcomes in 600 patients,Cpx-351,,Venetoclax,
95,Venetoclax-azacitidine in combination with chidamide and CAG versus daunorubicin and cytarabine in newly diagnosed AML,"Azacitidine, CAG, Chidamide",,"Cytarabine, Daunorubicin",
96,"Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM) - interim results from the randomized Phase III COBRA trial.","Carfilzomib, Dexamethasone, Lenalidomide",,"Bortezomib, Dexamethasone, Lenalidomide",
97,3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma,"AVD, Nivolumab",,"AVD, Brentuximab Vedotin",
98,Final analysis of the Phase III GHSG HD21 trial: PET-guided brecadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma,Brecadd,,Ebeacopp,
99,Clinical prognostication in the SWOG 1826 randomized clinical trial of nivolumab-AVD versus brentuximab-AVD: Performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI),"AVD, Nivolumab",,"AVD, Brentuximab Vedotin",
100,Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials,"Ibrutinib, Venetoclax",,"Acalabrutinib, Venetoclax",
101,"Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study",Mitoxantrone,,Chidamide,
102,Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study,Acalabrutinib,,"Obinutuzumab, Venetoclax",
103,Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma - final results from a randomized investigator-initiated trial,Daratumumab,,Lenalidomide,
104,Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND),"Lenalidomide, Selinexor",,Lenalidomide,
105,"Health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (NDMM) eligible for transplantation and treated with isatuximab, lenalidomide, bortezomib, and dexamethasone (Isa-RVd) versus rvd alone: Results from part 1 of the GMMG-HD7 study","Bortezomib, Dexamethasone, Isatuximab, Lenalidomide",,"Bortezomib, Dexamethasone, Lenalidomide",
106,"Comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus belantamab mafodotin (belamaf), bortezomib, and dexamethasone and versus belamaf, pomalidomide, and dexamethasone in patients with relapsed / refractory multiple myeloma (RRMM) previously treated with 1-3 prior lines of therapy using a matching-adjusted indirect comparison",Ciltacabtagene Autoleucel,,"Belantamab Mafodotin, Bortezomib, Dexamethasone",
107,"Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study",Isatuximab,,"Dexamethasone, Isatuximab, Pomalidomide",
108,Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the auriga study,"Daratumumab, Lenalidomide",,Lenalidomide,
109,A single-centre comparison of thiotepa-treosulfan versus thiotepa-busulfan based conditioning regimens in adults with haematological malignancies undergoing allogeneic haematopoietic stem cell transplant.,Thiotepa-Treosulfan,,Busulfan-Thiotepa,
110,Comparative outcomes of fludarabine-melphalan versus fludarabine-busulfan reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A systematic review and meta-analysis,"Fludarabine, Melphalan",,"Busulfan, Fludarabine",
111,Treosulfan-based vs. busulfan-based conditioning for hematopoietic stem cell transplantation: A systematic review and meta-analysis.,Treosulfan,,Busulfan,
112,Melphalan versus cyclophosphamide combined with fludarabine and low dose total body irradiation (TBI) prior to ptcy-based allogeneic transplantation,Melphalan,,"Cyclophosphamide, Fludarabine",
113,Salvage allogeneic hematopoietic stem cell transplantation conditioning regimens for relapsed/refractory acute leukemia: Efficacy of radiotherapy combined with CLAG vs FLAG,"Allogeneic Hematopoietic Stem Cell, CLAG",,FLAG,
114,"10-day decitabine versus conventional chemotherapy (""3+7"") followed by allografting in AML patients ? 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group",Decitabine,,3+7,
115,S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) VS. venetoclax and rituximab (VR) in previously untreated waldenstrom's macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL).,"Ibrutinib, Rituximab",,"Rituximab, Venetoclax",
116,Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis,Cyclophosphamide,,"Methotrexate, Tacrolimus",
117,"Venetoclax-azacitidine-chidamide plus CAG (CACAG-VEN) versus ""3+7"" induction chemotherapy in Intermediate-adverse Acute Myeloid Leukemia: Efficacy and safety","Azacitidine, CAG, Chidamide, Venetoclax",,3+7,
118,Real-world evidence demonstrates superior overall survival and favorable safety of avapritinib over midostaurin in newly diagnosed advanced systemic mastocytosis,Avapritinib,,Midostaurin,
119,"Fludarabine and total body irradiation 800 cgy or 1125 cgy for allogeneic stem cell transplant using graft versus host disease prophylaxis with post-transplant cyclophosphamide and tacrolimus, without mycophenolate mofetil (OmitMMF trial)",Fludarabine,,"Cyclophosphamide, Tacrolimus",
120,"Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia:a phase III, prospective, multicenter, randomized controlled trial","Decitabine, Venetoclax",,"Azacitidine, Venetoclax",
121,Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma,"Obinutuzumab, Zanubrutinib",,Obinutuzumab,
122,First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO),Rituximab,,"CHOP, Rituximab",
123,Oral etoposide vs intravenous daunorubicin plus ATRA-RIF as induction therapy for low-risk acute promyelocytic leukemia: A phase II randomized controlled Trial,Etoposide,,Daunorubicin,
124,Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis,Mosunetuzumab,"Obinutuzumab, Polatuzumab Vedotin",,
125,"An open-label, Phase 2 study of dapolsertib (MEN1703, SEL24) as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma",Dapolsertib,Glofitamab,,
126,"A chemotherapy-free regimen of sintilimab, rituximab, and lenalidomide ± polatuzumab vedotin in elderly patients with newly diagnosed diffuse large B-cell lymphoma","Lenalidomide, Rituximab, Sintilimab",Polatuzumab Vedotin,,
127,Thrombotic outcomes in sickle cell disease patients treated with crizanlizumab with or without hydroxyurea: A real-world retrospective cohort analysis using the trinetx database,Crizanlizumab,Hydroxyurea,,
128,Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up,"Bendamustine, Rituximab",Acalabrutinib,,
129,"Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results",Golcadomide,Rituximab,,
130,"Real-world use, safety, and efficacy of teclistamab with or without prophylactic tocilizumab in relapsed/refractory multiple myeloma; Results from the danish ABCD study.",Teclistamab,Tocilizumab,,
131,"Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study","Bendamustine, Obinutuzumab, Orelabrutinib, Rituximab",Orelabrutinib,,
132,Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL),Mesutoclax,Orelabrutinib,,
133,"The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial",RVd,"Autologous Stem Cell, RVd",,
134,"Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)",KRd,Daratumumab,,
135,Real-world incidence of bleeding events in patients with chronic lymphocytic leukemia treated with acalabrutinib +/- obinutuzumab and requiring direct oral anticoagulation,Acalabrutinib,Obinutuzumab,,
136,"A phase III, multicenter, randomized, placebo controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult sickle cell disease patients with frequent vaso-occlusive crises: The sparkle study",Crizanlizumab,"Hydroxycarbamide, Hydroxyurea",,
137,ITCC-101/APAL2020D: A randomized Phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamycin with or without venetoclax in children with relapsed Acute Myeloid Leukemia,"Cytarabine, Fludarabine, Gemtuzumab Ozogamycin",Venetoclax,,
138,"Motixafortide (CXCR4 inhibition) alone and in combination with natalizumab (VLA-4 inhibition) to mobilize hematopoietic stem cells for gene therapy in sickle cell disease: A first-in-human, safety and feasibility study",Motixafortide,Natalizumab,,
139,Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial,"Acalabrutinib, Brexucabtagene Autoleucel, Rituximab",Brexucabtagene Autoleucel,,
140,Bortezomib-melphalan-prednisone (VMP) +/- daratumumab (DVMP) vs. lenalidomide-dexamethasone (Rd) +/- daratumumab (DRd) in transplant-ineligible real-life multiple myeloma patients: Results from the randomized phase IV real MM trial,"Bortezomib, Melphalan, Prednisone",Daratumumab,,
141,Analysis of predictive factors for POD24 in patients with previously untreated mantle cell lymphoma receiving bendamustine-rituximab with or without acalabrutinib in the phase 3 ECHO trial,Bendamustine/Rituximab,Acalabrutinib,,
142,Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide,"Bendamustine, Rituximab","Bortezomib, Lenalidomide",,
143,Post-transplant bendamustine (PT-BEN) with or without cyclophosphamide for gvhd prophylaxis after haplo-identical or matched unrelated donor transplants: A phase I/II trial,Bendamustine,Cyclophosphamide,,
144,Efficacy and safety of first-line orelabrutinib combined with obinutuzumab (With or Without Bendamustine) in high-risk marginal zone lymphoma: Results from the orchid study,"Obinutuzumab, Orelabrutinib",Bendamustine,,
145,Trial in progress - a randomized study of ASTX727 with or without Iadademstat in accelerated/blast-phase myeloproliferative neoplasms,ASTX-727,Ladademstat,,
146,Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukemia: A multi-center phase II expansion study,"Cytarabine, Venetoclax",Idarubicin,,
147,"Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML - the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups",Cytarabine,Dexamethasone,,
148,A phase I dose escalation and expansion trial of lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) alone and in combination with venetoclax/HMA in Relapsed/Refractory AML/MDS,Lyt-200,Venetoclax,,
149,"Orelabrutinib, rituximab, and thiotepa (ORT) in combination with or without high-dose methotrexate in untreated primary central nervous system lymphoma","Orelabrutinib, Rituximab, Thiotepa",Methotrexate,,
150,"Chemotherapy-free induction with pomalidomide, orelabrutinib, and rituximab (POR) followed by high-dose methotrexate,rituximab and orelabrutinin (ROM) in newly diagnosed primary CNS lymphoma: Interim analysis of a phase II study","Orelabrutinib, Rituximab","Methotrexate, Rituximab",,
151,Synergistic apoptotic effect by the combination of clk inhibitor CTX-712 and BCL-2 inhibitor ABT-199 with or without azacytidine in AML and MDS,"Abt-199, CTX-712",Azacytidine,,
152,XPO1 inhibitor WJ01024 monotherapy or in combination with ruxolitinib in myelofibrosis,Wj01024,Ruxolitinib,,
153,"An open-label, Phase I/II clinical trial of romaciclib (RVU120) as monotherapy and in combination with ruxolitinib in patients with intermediate or high-risk, primary or secondary myelofibrosis (POTAMI-61)",Romaciclib,Ruxolitinib,,
154,An open-label phase I study of JAK inhibitor ruxolitinib with and without CTLA-4 ig abatacept for the prophylaxis of graft-versus-host ddsease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation,Ruxolitinib,Abatacept,,
155,Update in Hemophilia Across the Lifespan: Novel Therapies/Gene Therapy/Issues in Older Patients,,,,
156,"High rates of severe maternal morbidity and preterm birth among pregnant individuals with sickle cell disease, a nationwide study from 2020-2024",,,,
157,ASH Clinical Practice Guidelines on Diagnosis of Iron Deficiency with and without Anemia,,,,
158,Hemoglobinopathies and Increased Risk of Venous Thromboembolism,,,,
159,The Changing Landscape of the Care of Patients With Immune-Mediated and Congenital TTP,,,,
160,Accurate and automated multi-center TCD velocity analysis using natural language processing,,,,
161,Hemoglobinopathies and Increased Risk of Venous Thromboembolism,,,,
162,Update in Hemophilia Across the Lifespan: Novel Therapies/Gene Therapy/Issues in Older Patients,,,,
163,Training Program Directors Workshop,,,,
164,Chromodomain helicase DNA binding protein CHD2 interacts with TET2 and regulates lineage defining transcription in hematopoietic stem and progenitor cells,,,,
165,Unravelling the epigenetic drivers of chip - MDS/CMML - AML progression through novel methylation-sensitive regulatory elements,,,,
166,Sickle cell disease in europe: A cross-border real-world data analysis from the radeep registry,,,,
167,Characterisation of the wnt signalling responsive surfaceome of myeloid cells reveals PLP2 as a regulator of haematopoietic cell proliferation and monocytic differentiation,,,,
168,Missense mutations in the PWWP domain of DNMT3A can cause cytoplasmic mislocalization of DNMT3A in AML cells,,,,
169,ASH Clinical Practice Guidelines on Diagnosis of Iron Deficiency with and without Anemia,,,,
170,The Changing Landscape of the Care of Patients With Immune-Mediated and Congenital TTP,,,,
171,"Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change",,,,
172,Medical Educators' Symposium,,,,
173,Comorbid COPD as a major independent predictor of post-discharge morbidity in adults hospitalized for sickle cell acute chest syndrome: A national propensity-matched analysis,,,,
174,"Comparative performance of khorana, padua, and improve-VTE risk assessment models for venous thromboembolism risk stratification in hospitalized oncology patients",,,,
175,Endothelial cell-derived mitochondrial transfer to Acute Myeloid Leukemia alters global gene expression to confer chemoresistance,,,,
176,Early interventions to reduce sickle cell childhood mortality in Africa (Global Burden of Disease Impact),,,,
177,ASH's SCD Initiative: 10 Years of Progress and a Look to the Future of Sickle Cell Disease Research and Care,,,,
178,The Changing Landscape of the Care of Patients With Immune-Mediated and Congenital TTP,,,,
179,Reassessing ASCT in patients aged 65-75 with multiple myeloma in the era of anti-CD38 therapies,,,,
180,Real-world experience with first-line regimens in transplant-ineligible patients with multiple myeloma,,,,
181,Medical Educators' Symposium,,,,
182,The weight of stress: Allostatic load as a predictor of vaso-occlusive episodes in adults with sickle cell disease,,,,
183,Phytosphingosine alleviates acute gvhd by inducing th cell differentiation to Tr1 through GPR120/IL-10 axis,,,,
184,Complementopathies: Modern Diagnosis and Management,,,,
185,Ornithine decarboxylase deficiency in donor T cells preserves strong GVL activity while attenuating acute and preventing steroid-resistant gut GVHD in a recipient tissue PD-L1-dependent manner,,,,
186,Update in Hemophilia Across the Lifespan: Novel Therapies/Gene Therapy/Issues in Older Patients,,,,
187,Medical Educators' Symposium,,,,
188,Spatial communication modules identify prognostic cell-cell signaling hubs in chronic graft-versus-host disease,,,,
189,Peripheral blood plasma proteomics reveals dysregulated cholesterol transport and complement pathways in myeloproliferative neoplasms,,,,
190,AML blasts and monocytic myeloid-derived suppressor cells (M-MDSC) inhibit human mucosal-associated invariant t (MAIT) cells activation.,,,,
191,Exploring the relationship between health-related stigma and perceived discrimination among adults with sickle cell disease,,,,
192,Impact of race and socioeconomics on access to T-cell engaging therapy in US patients with relapsed/refractory multiple myeloma (RRMM),,,,
193,Implementing linkage coordination: Patient experiences in the recruitment and engagement in care to impact practice enhancement (RECIPE) for sickle cell disease study,,,,
194,Complementopathies: Modern Diagnosis and Management,,,,
195,Synergistic effects of ASXL1 and BCOR on hematopoiesis and MDS/AML progression,,,,
196,Complementopathies: Modern Diagnosis and Management,,,,
197,"New evidence indicates that the NLRP3 inflammasome in hematopoietic stem and progenitor cells (HSPCs) maintains proper mitochondrial electron transport chain function and affects both cellular trafficking and metabolism through a gasdermin pore-mediated, alarmin-release-dependent mechanism",,,,
198,Medical Educators' Symposium,,,,
199,NEAT1-triggered collateral activity of CRISPR/Cas13 exhibits antileukemic activity,,,,
200,Real-world sequencing of anti-BCMA CAR T-cells and bispecific T-cell engagers in Relapsed/Refractory multiple myeloma: A multi-country analysis,,,,
201,Medical Educators' Symposium,,,,
202,Development of a prediction model for maternal pregnancy complications in sickle cell disease,,,,
203,Biology-Based Management of Iron Toxicity and Overload in Hematology Practice,,,,
204,"T-cell redirecting therapies in multiple myeloma: Barriers and knowledge gap among patients, community physicians, and caregivers",,,,
205,Beyond the genome: An integrated multi-omics approach to uncover histone ptm-driven metabolic and proteomic regulation in AML,,,,
206,"Myeloma mortality trends in the United States (Excluding Puerto Rico), 1999-2021, and future projections using ARIMA modeling and machine learning",,,,
207,Biology-Based Management of Iron Toxicity and Overload in Hematology Practice,,,,
208,STAG2 mutation preserves a stem cell phenotype in FLT3-ITD-mediated MDS to leukemia transformation,,,,
209,Medical Educators' Symposium,,,,
210,Humanistic and economic burden among caregivers of adults and children with sickle cell disease and recurrent vaso-occlusive crises,,,,
211,Unpredictability of caregiver gaps in multiple myeloma: Results from a survey of >1000 patients,,,,
212,Medical Educators' Symposium,,,,
213,Low expression of TMSB10 in bone marrow in MDS patients with T cell large granular lymphocytic proliferation is associated with improved immune tolerance status of T cells and disease prognosis: Clinical data and single-cell sequencing analysis,,,,
214,Microbiota metabolite phenlyacetylglycine alleviates acute graft-versus-host diseases,,,,
215,Heterogeneous TP53 mutation subtypes define prognostic classification in Mantle Cell Lymphoma,,,,
216,Hnrnpk haploinsufficiency in del(9q) Acute Myeloid Leukemia reveals targetable vulnerabilities,,,,
217,Shifting symptom profiles and accelerated diagnosis in AL amyloidosis: Findings from ARC community surveys 2022-2024,,,,
218,ZFP36L2 as a promising therapeutic target in acute graft-versus-host disease: Evidence from murine models and clinical validation,,,,
219,Utility of 18F-FDG PET/CT for response assessment in marginal zone lymphomas: Preliminary results of the IELSG44 international study,,,,
220,ASH-EHA Joint Symposium,,,,
221,"Molecular Diagnostics for Clinical Classical Hematologists: When to Order, What to Order, What It Means, and When to Refer to Genetics?",,,,
222,Transition to IRD maintenance after DRD induction significantly deepens response in transplant-ineligible NDMM: A prospective multicenter study,,,,
223,PTP4A3: A potential therapeutic target in Acute Myeloid Leukemia,,,,
224,Health status of Ugandan children born with sickle cell anemia and congenital HIV identified through newborn screening,,,,
225,What remains matters: Real-world impact of measurable residual disease testing in multiple myeloma,,,,
226,Biology-Based Management of Iron Toxicity and Overload in Hematology Practice,,,,
227,Inflammatory transcriptome dominates Indian AML: High iscore predicts poor outcomes even in genomically favorable subtypes and reveals regional immune-molecular divergence,,,,
228,Understanding access and treatment challenges in multiple myeloma care,,,,
229,ASH-EHA Joint Symposium,,,,
230,"Molecular Diagnostics for Clinical Classical Hematologists: When to Order, What to Order, What It Means, and When to Refer to Genetics?",,,,
231,Treating Fairly Rounds Lunch,,,,
232,Patient-driven insights in sickle cell disease: Results from a global survey informing public health strategies,,,,
233,Humanistic and economic burden among caregivers of adults and children with transfusion dependent ?-thalassemia,,,,
234,Physiologic oxygen expansion of murine lineage negative bone marrow cells enhances lymphocyte recovery following transplantation,,,,
235,Ernest Beutler Lecture and Prize,,,,
236,HDAC inhibitors potentiate the efficacy of antineoplastic agents in acute megakaryoblastic leukemia via dual activation of apoptosis and pyroptosis,,,,
237,Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study,,,,
238,The burden of myeloma treatment routes and locations on patients and families: Insights from a Pan-European survey,,,,
239,Safety and efficacy of triple vs quadruple therapy in transplant ineligible multiplemyeloma patients - a meta-analysis of randomized controlled trials,,,,
240,Expression of the erythroid controller of systemic iron homeostasis erythroferrone is cis-regulated,,,,
241,Targeted Therapy for AML (Triplets and More),,,,
242,Targeted Therapy for AML (Triplets and More),,,,
243,Analysis of the role of baseline PET/CT in a prospective study of unselected patients: The UK MCL biobank,,,,
244,Early Faculty Career Development Session,,,,
245,"Molecular Diagnostics for Clinical Classical Hematologists: When to Order, What to Order, What It Means, and When to Refer to Genetics?",,,,
246,Therapeutic effects of Tmprss6 suppression are negated by iron overload in a mouse model of beta-thalassemia,,,,
247,The role of G0S2 in FLT3+ AML bone marrow microenvironment and metabolism,,,,
248,Oncofetal RNA-binding proteins IGF2BP suppress innate immunity signaling pathways in leukemia stem cells,,,,
249,Platelet priming in MPN triggers pro-thrombotic intermediate affinity state in ?IIb?3 integrin,,,,
250,Early Faculty Career Development Session,,,,
251,CXCR6-dependent ILC3 migration to the intestinal stem cell compartment promotes epithelial regeneration after conditioning-related intestinal injury,,,,
252,Targeted Therapy for AML (Triplets and More),,,,
253,TIM3-Galectin9 axis drives CSF-1R-independent senescent macrophage and TSCM crosstalk in chronic graft-versus-host disease,,,,
254,Inhibition of DRP1-FIS1-Mediated mitochondrial fission as a novel strategy to prevent gvhd,,,,
255,Complement-induced procoagulant platelets in patients with antiphospholipid antibodies,,,,
256,Transcriptional programming by GATA3 regulates CD4+ T cell GM-CSF production in the gastrointestinal tract during graft versus host disease,,,,
257,Early Faculty Career Development Session,,,,
258,Haploidentical and neonatal combined transplant generates GVL effect in a murine model of haplo-cord transplant.,,,,
259,"Chronic myeloid leukemia (CML) evolution is not encoded in single-cell microstates, but emerges from population-level macrostates",,,,
260,Early Faculty Career Development Session,,,,
261,"Risk of death and comorbidities in ?-thalassemia carriers identified by consecutive genotyping: A prospective cohort study of 467,242 general population individuals",,,,
262,"PRMT1 drives platelet metabolic reprogramming, thromboinflammation, and antiplatelet drug resistance",,,,
263,Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM),,,,
264,IFN?-driven MHC class II expression by intestinal epithelial cells dictates local cytolytic Th1 cell differentiation and intestinal stem cell loss,,,,
265,Causes of death in young children with sickle cell disease and sickle trait in young children investigated by the child health and mortality prevention surveillance (CHAMPS) network,,,,
266,"Iron overload is prevalent, likely underdiagnosed and undertreated in sickle cell disease: A real-world report from the ASH research collaborative",,,,
267,Delivery of HFE mRNA by lipid nanoparticles corrects iron parameters and BMP responsiveness in murine hereditary hemochromatosis,,,,
268,Early Faculty Career Development Session,,,,
269,Ferroportin Q248H mutation is associated with the less weight loss in persons with HIV-1,,,,
270,A TLR4-HSP70 efferocytic program in thymic macrophages sustains thymic homeostasis and T cell output,,,,
271,Real-world outcomes for anti-CD38 monoclonal antibody-naive and exposed patients receiving treatment for multiple myeloma,,,,
272,Regulatory long noncoding RNA of T cells (ReLoT/LINC00402) impairs Ror?t+ allogeneic T cells,,,,
273,"Post-SCT Maintenance Strategies in Leukemia: Who, When, and Why?",,,,
274,Stability and evolution of individual-level biomarker patterns across repeated vaso-occlusive crises in sickle cell disease,,,,
275,"A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor (TANGENT).",Emactuzumab,,,
276,A phase II study of encorafenib and cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E-mutated metastatic colorectal cancer (mCRC).,"Cetuximab, Encorafenib, FOLFIRI",,,
277,"First safety analysis of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluoruracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC).","5-Fluoruracil/Folinic Acid, Liposomal Irinotecan, Oxaliplatin",,,
278,"A multiregional, randomized, controlled, open-label, phase 3 study of the anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) arcotatug tavatecan (IBI343) in gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Trial in progress.",Arcotatug Tavatecan,,,
279,EMERALD-Y90: A phase 2 study to evaluate transarterial radioembolization (TARE) followed by durvalumab (D) and bevacizumab (B) for the treatment of participants (pts) with unresectable hepatocellular carcinoma (uHCC) eligible for embolization.,"Bevacizumab, Durvalumab",,,
280,Survival of induction aumolertinib followed by aumolertinib and concurrent radiotherapy (RT) in unresectable EGFR-mutated stage III NSCLC: Final analysis of the phase III ADVANCE trial and real-world data.,Aumolertinib,,,
281,IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers-The B3 Thymomas and Thymic Carcinomas Cohort.,"Domvanalimab, Zimberelimab",,,
282,"A global phase 2/3, randomized, open-label trial of BNT327/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC).",PM8002/BNT327,,,
283,"Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced, metastatic gastroesophageal adenocarcinoma: The phase 3, randomized LEAP-015 study.","Lenvatinib, Pembrolizumab",,,
284,Optimizing post–chimeric antigen receptor (CAR) T cell monitoring: Evidence across lisocabtagene maraleucel (liso-cel) pivotal clinical trials and real-world experience.,"CAR T-Cell, Lisocabtagene Maraleucel",,,
285,Real-world safety and effectiveness of avelumab in immune-compromised (IC) and non-IC patients with Merkel cell carcinoma (MCC): Results from a prospective German registry (MCC-TRIM).,Avelumab,,,
286,"Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ study.","Bortezomib, Dexamethasone, Isatuximab, Lenalidomide",,,
287,"SHR-A1811 as neoadjuvant therapy for HR-positive, HER2-low breast cancer: A single-arm, phase II clinical study.",SHR-A1811,,,
288,Promising early results of MHB088C (B7-H3 ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) from a phase 1/2 multicenter study.,MHB088C,,,
289,Neoadjuvant lenvatinib plus pembrolizumab for resectable clear-cell renal cell carcinoma (PELUR): A prospective phase 2 study.,"Lenvatinib, Pembrolizumab",,,
290,Monotherapy of envafolimab in patients with high tumor mutational burden advanced solid tumors: Results from a phase II clinical trial.,Envafolimab,,,
291,IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers-The Anaplastic Thyroid Carcinomas Cohort.,"Domvanalimab , Zimberelimab",,,
292,"Single low-dose 5-mg versus 8-mg dexamethasone with NEPA for the 168-h prevention of highly or moderately emetogenic (high-risk patients) chemotherapy-induced nausea/vomiting: An open-label, randomised, controlled, phase 3 trial.","Dexamethasone, NEPA",,,
293,"Efficacy and safety of MHB088C, a novel B7-H3-targeted ADC, in patients with relapsed extensive-stage small cell lung cancer (ES-SCLC): Subgroup analysis from a phase 1/2 multicenter study.",MHB088C,,,
294,Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial.,Vimseltinib,,,
295,"IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with R/R STS: A phase Ib expansion study.",IMM2510,,,
296,Comparative efficacy of cabozantinib or lenvatinib following atezolizumab plus bevacizumzb in patients with advanced hepatocellular cancer.,"Atezolizumab, Bevacizumab, Cabozantinib, Lenvatinib",,,
297,"A phase 1a/1b trial in relapsed/refractory T-cell non-Hodgkin lymphoma to determine the safety profile, pharmacology, and maximum tolerated dose of ST-001, an intravenous fenretinide phospholipid suspension (12.5 mg/mL).",ST-001,,,
298,"IBI354, an anti-HER2 antibody-drug conjugate, in patients with locally advanced unresectable or metastatic ovarian cancers: Updated results from a phase I trial.",IBI354,,,
299,Safety and efficacy analysis of DNV3 plus toripalimab and chemotherapy in advanced melanoma: An open-label investigator-initiated trial.,Toripalimab,,,
300,COBRA: Assessment of the efficacy of 64Cu-SAR-bisPSMA using histopathology and standard of care imaging as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy.,64Cu-SAR-bisPSMA,,,
301,"A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [225Ac]Ac-FL-020, an anti-PSMA radioconjugate, in patients with metastatic castration-resistant prostate cancer (mCRPC).",[225Ac]Ac-FL-020,,,
302,Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343.,IBI343,,,
303,"A phase 1 study of fixed-dose regimens of serplulimab, an anti-PD-1 antibody, in patients with advanced solid tumors.",Serplulimab,,,
304,"PROCEADE PanTumor: A phase 1b/2, multicenter study of precemtabart tocentecan (M9140), an anti-CEACAM5 antibody-drug conjugate (ADC) with exatecan payload, in patients with advanced solid tumors.","Exatecan, Precemtabart Tocentecan",,,
305,Tarlatamab for Extensive-Stage Small Cell Lung Cancer,Tarlatamab,,,
306,Epcoritamab for Relapsed or Refractory Follicular Lymphoma,Epcoritamab,,,
307,Datopotamab Deruxtecan for Metastatic Hormone Receptor Positive HER2 Low or Negative Breast Cancer,Datopotamab Deruxtecan,,,
308,Vorasidenib for Grade 2 Astrocytoma or Oligodendroglioma With a Susceptible IDH1 or IDH2 Mutation,Vorasidenib,,,
309,Reduced dose PTCy in patients with acute myeloid leukemia receiving matched unrelated donor allogeneic hematopoietic stem cell transplantation.,"Allogeneic Hematopoietic Stem Cell, Cyclophosphamide",,,
310,Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study.,"Azacitidine, Bexmarilimab",,,
311,Dosing decitabine and venetoclax for terminal differentiation to improve outcomes in TP53 mutant MDS and AML.,"Decitabine, Venetoclax",,,
312,"IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF).","Imetelstat, Ruxolitinib",,,
313,Efficacy and safety of asciminib (ASC) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial.,Asciminib,,,
314,Psychosocial digital application for caregivers of patients undergoing hematopoietic stem cell transplantation (HSCT): A randomized controlled trial.,Hematopoietic Stem Cell,,,
315,A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).,KITE-363,,,
316,WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma.,Zilovertamab Vedotin,,,
317,"Sintilimab (anti-PD-1 antibody) combined with chidamide (an oral subtype-selective HDACi) followed by P-GemOx regimen in patients with treatment-naïve extranodal natural killer/T cell lymphoma (TN-ENKTL): A multicenter, open-label, single-arm, phase II study (SCENT-2 trial).","Chidamide, Sintilimab",,,
318,"Sintilimab (anti-PD-1) plus ifosfamide, carboplatin, and etoposide (ICE) in second-line classical Hodgkin lymphoma (cHL): Results of a multicenter, randomized, controlled, double-blind phase 3 study (ORIENT-21).","Carboplatin, Etoposide, Ifosfamide, Sintilimab",,,
319,Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203).,"AB-101, AFM13",,,
320,Treatment rechallenge after trastuzumab-deruxtecan–related interstitial lung disease: A multi-institution cohort study.,Trastuzumab Deruxtecan,,,
321,Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+ advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial.,"Ribociclib, Trastuzumab",,,
322,HER2-ADC trastuzumab rezetecan (SHR-A1811) in HER2-positive breast cancer with brain metastases: Update results from REIN trial.,Trastuzumab Rezetecan,,,
323,A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases.,"Adebrelimab, Bevacizumab",,,
324,Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study.,Sacituzumab Tirumotecan,,,
325,"Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+/HER2− metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D).",PF-07248144,,,
326,Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after 2 or more HER2-directed chemotherapies (KM-10A/KCSG BR18-13).,"Gedatolisib, Trastuzumab",,,
327,"DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: Preliminary results from the phase 1/2a trial.",DB-1310,,,
328,"Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations.",IZA-BREN,,,
329,"Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC).",IZA-BREN,,,
330,"Safety and efficacy of TQB2102, a novel bispecific anti-HER2 antibody–drug conjugate, in patients with advanced solid tumors: Preliminary data from the first-in-human phase 1 trial.",TQB-2102,,,
331,Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial.,Obrixtamig,,,
332,[212Pb]VMT-α-NET therapy in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs): Dose-limiting toxicity (DLT) observation participants after 1 year follow-up and preliminary report for expansion participants.,[212Pb]VMT-Alpha-NET,,,
333,Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion: NCT00626990.,Temozolomide,,,
334,A phase 2 study of pemigatinib for pre-treated glioblastoma or other gliomas with activating FGFR1-3 alterations: Results from FIGHT-209.,Pemigatinib,,,
335,A phase II study of asandeutertinib (TY-9591) in advanced NSCLC patients with EGFR-positive mutations and brain metastases.,Asandeutertinib,,,
336,"Patritumab deruxtecan (HER3-DXd) in active brain metastases (BM) from metastatic breast (mBC) and non–small cell lung cancers (aNSCLC), and leptomeningeal disease (LMD) from advanced solid tumors: Results from the TUXEDO-3 phase II trial.",Patritumab Deruxtecan,,,
337,A phase II study of an anti-telomerase CD4+ T-helper vaccine (UCPVax) with or without temozolomide in newly diagnosed glioblastoma.,Temozolomide,,,
338,INB-200: Phase 1 study of gene-modified autologous gamma-delta (γδ) t cells in newly diagnosed glioblastoma multiforme (GBM) patients receiving maintenance temozolomide (TMZ).,"Gamma-Delta T Cell, Temozolomide",,,
339,Immunological correlates from phase I study of CARv3-TEAM-E in patients with recurrent glioblastoma (GBM): INCIPIENT trial.,CARV3-TEAM-E,,,
340,First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses.,"Cetuximab, Encorafenib, mFOLFOX6",,,
341,Tissue-free circulating tumor DNA assay and patient outcome in a phase III trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147).,Folfox,,,
342,Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 (phase 1b).,"FOLFIRI, Panitumumab, Sotorasib",,,
343,"Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in KRAS G12C-mutant advanced colorectal cancer.","Cetuximab, Olomorasib",,,
344,The KRAS G12C inhibitor MK-1084 for KRAS G12C–mutated advanced colorectal cancer (CRC): Results from KANDLELIT-001.,MK-1084,,,
345,Debate: Osimertinib Alone as Front-Line Therapy for a Patient With Metastatic EGFR Non–Small Cell Lung Cancer,Osimertinib,,,
346,Development of Afami-Cel–Engineered Cell Therapy for Advanced Synovial Sarcoma,Afamitresgene Autoleucel,,,
347,Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL: Results in SEQUOIA arm D.,"Venetoclax, Zanubrutinib",,,
348,Phase 1/2 studies of DZD8586 in CLL/SLL patients after covalent or non-covalent BTK inhibitors and BTK degraders.,DZD8586,,,
349,SEQUOIA 5-year follow-up in arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).,Zanubrutinib,,,
350,"A phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/refractory non-Hodgkin lymphoma.",XNW-50004,,,
351,"CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): Data from a phase 1b/2 study.","Gemcitabine, Oxaliplatin, Rituximab, SHRA-A1912",,,
352,Fixed duration subcutaneous (SC) mosunetuzumab (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): Interim results from the phase II MorningSun study.,Mosunetuzumab,,,
353,Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO.,"Gemcitabine, Glofitamab, Oxaliplatin",,,
354,Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study.,"Ibrutinib, Venetoclax",,,
355,DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients with high-risk cytogenetic features.,"Belantamab Mafodotin, Dexamethasone",,"Bortezomib, Pomalidomide",
356,"Overall survival (OS) and duration of response for transfusion independence (TI) in erythropoiesis stimulating agent (ESA)–naive patients (pts) with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) treated with luspatercept (LUSPA) vs epoetin alfa (EA) in the COMMANDS trial.",Luspatercept,,Epoetin Alfa,
357,Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW.,"Ipilimumab, Nivolumab",,Nivolumab,
358,"Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial).","Anlotinib, Bevacizumab",,Bevacizumab,
359,A multicenter randomized phase III study for recurrent glioblastoma comparing bevacizumab alone with dose-dense temozolomide followed by bevacizumab: JCOG1308C.,"Bevacizumab, Temozolomide",,"Bevacizumab, Temozolomide",
360,"A global phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma.",Niraparib,,Temozolomide,
361,"Telisotuzumab adizutecan (ABBV-400; Temab-A) monotherapy vs trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer with increased c-Met protein expression: An open-label, randomized, phase 3 trial.",Telisotuzumab Adizutecan,,Bevacizumab,
362,"OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS/BRAF wild-type metastatic colorectal cancer.",Amivantamab,,"Cetuximab, Folfiri, Folfox",
363,"OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.","Amivantamab, FOLFIRI",,"Bevacizumab, Cetuximab, Folfiri",
364,"mFOLFOX6 + bevacizumab + PD-1 monoclonal antibody vs. mFOLFOX6 in locally advanced pMMR/MSS CRC: A multicenter, randomized controlled phase III study (BASKETIII).","Bevacizumab, mFOLFOX6",,mFOLFOX6,
365,Doxorubicin-based chemotherapy vs gemcitabine/docetaxel in uterine leiomyosarcoma (ULMS).,Doxorubicin,,"Docetaxel, Gemcitabine",
366,"Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.",Vepdegestrant,,Fulvestrant,
367,"A real-world, propensity-matched analysis of second-line (2L) FOLFIRI-Ram versus Ram-Pac in advanced upper gastrointestinal cancers.","Folfiri, Ramucirumab",,"Paclitaxel, Ramucirumab",
368,LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma.,"Lenvatinib, Pembrolizumab",,Lenvatinib,
369,"A randomized, double-blinded, international phase III trial comparing HLX22 in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy with or without pembrolizumab for first-line treatment for HER2-positive locally advanced or metastatic G/GEJ cancer.","Hlx22, Trastuzumab",,"Pembrolizumab, Trastuzumab",
370,"AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study.","Axitinib, Nivolumab",,Nivolumab,
371,A phase II (Alliance/A091802) randomized trial of avelumab plus cetuximab vs. avelumab alone in advanced cutaneous squamous cell carcinoma (cSCC).,"Avelumab, Cetuximab",,Avelumab,
372,"Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.",Tagitanlimab,,"Cisplatin, Gemcitabine",
373,A randomized study of neoadjuvant REGN7075 + cemiplimab + chemotherapy (chemo) vs cemiplimab + chemo in patients (pts) with resectable non-small cell lung cancer (NSCLC).,"Cemiplimab, REGN7075",,Cemiplimab,
374,Phase 2 peri-operative study of fianlimab + cemiplimab + chemotherapy versus cemiplimab + chemotherapy in resectable early-stage non-small cell lung cancer (NSCLC).,"Cemiplimab, Fianlimab",,Cemiplimab,
375,"TIGOS-LS, an open-label, randomized study of BMS-986489 vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer.",BMS-986489,,Durvalumab,
376,"The TIGOS trial: A randomized, double-blind phase 3 trial of atigotatug + nivolumab fixed-dose combination with chemotherapy vs atezolizumab with chemotherapy in patients with 1L extensive-stage small cell lung cancer (ES-SCLC).","Atigotatug, Nivolumab",,Atezolizumab,
377,"A global phase III, double-blind, randomized trial of BNT327/PM8002 plus chemotherapy (chemo) compared to atezolizumab plus chemo in patients (pts) with first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).",PM8002,,Atezolizumab,
378,Acolbifene vs tamoxifen for breast cancer prevention in premenopausal women at high risk for breast cancer.,Acolbifene,,Tamoxifen,
379,A phase 2 study of HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy as first-line therapy in advanced squamous non-small cell lung cancer.,"HLX07, Serplulimab",,Serplulimab,
380,Ripretinib versus sunitinib in imatinib-resistant gastro-intestinal stromal tumor with KIT Exon 11 mutations: A systematic review and meta-analysis.,Ripretinib,,Sunitinib,
381,Electronic patient reported outcomes in breast cancer patients receiving adjuvant chemotherapy with doxorubicin/cyclophosphamide combined with paclitaxel compared to patients receiving docetaxel/cyclophosphamide.,"Cyclophosphamide, Doxorubicin, Paclitaxel",,"Cyclophosphamide, Docetaxel",
382,Efficacy and safety of busulfan-fludarabine versus busulfan-cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplant in hematologic malignancy patients: A meta-analysis of randomized controlled trials and observational studies.,"Busulfan, Fludarabine, Hematopoietic Stem Cell",,"Busulfan, Cyclophosphamide",
383,Comparing the bleeding risk in hepatocellular carcinoma patients treated with atezolizumab/bevacizumab versus durvalumab plus tremelimumab.,"Atezolizumab, Bevacizumab",,"Durvalumab, Tremelimumab",
384,Cardiovascular adverse events in multiple myeloma patients: A comparative study analysis of daratumumab vs. lenalidomide.,Daratumumab,,Lenalidomide,
385,Retrospective comparison of abatacept (Aba) and half-dose posttransplant cyclophosphosphamide (PTCy) compared with standard dose PTCy GVHD prophylaxis.,Abatacept,,Cyclophosphosphamide,
386,Effectiveness and safety of the amivantamab to lazertinib versus lazertinib alone in EGFR mutant metastatic non-small-cell lung cancer: Systematic review and meta-analysis.,"Amivantamab, Lazertinib",,Lazertinib,
387,Efficacy and safety of nivolumab and docetaxel combination therapy versus nivolumab monotherapy for the treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis.,"Docetaxel, Nivolumab",,Nivolumab,
388,Comparative efficacy and safety of donafenib versus bevacizumab in combination with immune checkpoint inhibitors and interventional therapy for advanced hepatocellular carcinoma: A retrospective cohort study.,Donafenib,,Bevacizumab,
389,Protein-bound paclitaxel/carboplatin compared to solvent-based paclitaxel/carboplatin in treatment of advanced stage of cervical cancer.,"Carboplatin, Paclitaxel",,"Carboplatin, Paclitaxel",
390,Comparative efficacy of adjuvant FOLFOX versus FLOT following neoadjuvant FLOT in locally advanced gastric cancer.,FOLFOX,,FLOT,
391,Safety and efficacy of sintilimab versus pembrolizumab in the treatment of advanced or recurrent pediatric malignancies: A real-world study in China.,Sintilimab,,Pembrolizumab,
392,"Risk of autoimmune hepatitis, non-infectious gastroenteritis, and colitis among patients with metastatic clear cell renal cell carcinoma (ccRCC) treated with pembrolizumab/axitinib vs nivolumab/ipilimumab.","Axitinib, Pembrolizumab",,"Ipilimumab, Nivolumab",
393,Concomitant treatment with 2nd generation hormone therapy and 177Lut PSMA versus 177Lut PSMA alone: Does it improve PSA response rates?,177Lut PSMA,,177Lut PSMA,
394,177Lu-vipivotide tetraxetan PSMA vs cabazitaxel in metastatic castration-resistant prostate cancer: A real-world analysis using the TriNetX database.,177Lu-Vipivotide Tetraxetan PSMA,,Cabazitaxel,
395,Outcomes of additional BCG versus sequential gemcitabine + docetaxel in BCG-exposed high-risk non–muscle-invasive bladder cancer.,Bacillus Calmette-Guerin,,"Docetaxel, Gemcitabine",
396,Belantamab mafodotin + pomalidomide + dexamethasone (BPd) vs daratumumab + bortezomib + dexamethasone (DVd) in relapsed/refractory multiple myeloma: An indirect comparison using patient-level data.,"Belantamab Mafodotin, Dexamethasone, Pomalidomide",,"Bortezomib, Daratumumab, Dexamethasone",
397,Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study.,"Pembrolizumab, Sacituzumab Govitecan",,Pembrolizumab,
398,Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.,"Pertuzumab, Trastuzumab Deruxtecan",,"Pertuzumab, Trastuzumab",
399,"ALTER-PA001: A multicenter, randomized study of anlotinib and benmelstobart in combination with AG chemotherapy vs. AG as first-line treatment for metastatic pancreatic cancer.","Anlotinib, Benmelstobart, Gemcitabine, Nab-Paclitaxel",,"Gemcitabine, Nab-Paclitaxel",
400,"A multi-centre, stratified, open, randomized, comparator-controlled, parallel group phase II trial comparing adjuvant treatment with 177Lu-DOTATATE to standard of care in patients after resection of neuroendocrine liver metastases (NELMAS).",177Lu-Dotatate,,,
401,NCI 10479: A phase I dose escalation-expansion trial of sunitinib malate plus lutetium (Lu-177) dotatate in somatostatin receptor positive pancreatic neuroendocrine tumors.,"177Lu-Dotatate, Sunitinib Malate",,,
402,"High-dose 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) chemoembolization for treatment-naïve patients with limited uveal melanoma hepatic metastases.","1,3-Bis-(2-Chloroethyl)-1-Nitrosourea",,,
403,Clinical utility of [18F]fluoroestradiol (FES) PET/CT to guide second-line treatment decision in patients with ER-positive HER2-negative metastatic breast cancer progressing on first-line endocrine therapy.,[18F]-Fluoroestradiol,,,
404,‘One button push’ fully automated PSMA PET quantification: Correlation with progression free and overall survival in patients undergoing [177Lu] Lu PSMA therapy for metastatic castrate resistant prostate cancer.,[177Lu] Lu PSMA,,,
405,"PSMA-delay castration (DC): An open-label, multicenter, randomized phase 3 study of [177Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer (OMPC).",[177Lu]Lu-PSMA-617,,,
406,STARLITE-1: Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.,"177Lu Girentuximab, Cabozantinib, Nivolumab",,,
407,STARLITE 2: Phase 2 study of nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC).,"177Lu-Girentuximab, Nivolumab",,,
408,Outcomes with 177 lutetium-dotatate (177Lu-dotatate) in olfactory neuroblastoma (ONB): A case series.,177Lu-Dotatate,,,
409,Interim safety and efficacy data of [212Pb]VMT01 in MC1R expressing melanoma.,[212Pb]VMT01,,,
410,Artificial intelligence to predict outcome after [177Lu]Lu-PSMA for metastatic castration-resistant prostate cancer: Preliminary results from a multicentric prospective study.,[177Lu]Lu-PSMA,,,
411,"Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with neuroendocrine tumors of the prostate: A phase 1/2, first-in-human trial.",[89Zr]Zr-DFO-SC16.56,,,
412,"Efficacy and safety of anlotinib combined with ¹³¹I therapy in the treatment of distant metastatic differentiated thyroid cancer: A single-arm, phase II clinical study.","131I, Anlotinib",,,
413,The role of [18F]16α-fluoro-17β-fluoroestradiol (FES) PET in predicting response to endocrine therapy (ET) in advanced breast cancer.,[18F]-16a-Fluoro-17b-Fluorohestradil,,,
414,Correlation of [68 Ga]Ga-PSMA-11 PET biodistribution with immunohistochemical PSMA expression in hepatocellular carcinoma: Results from the prospective study MORE-PSMA.,[68 Ga]Ga-PSMA-11,,,
415,Safety and antitumor activity of 177Lu-catelase: A preliminary clinical study in soft tissue sarcoma.,177Lu-Catalase,,,
416,First-in-human study of 177Lu-JH020002 in patients with metastatic castration-resistant prostate cancer.,177Lu-JH020002,,,
417,A randomized phase III trial investigating platinum and taxane chemotherapy in metastatic castration resistant prostate cancer (mCRPC) patients with alterations in DNA damage response (DDR) genes (OPTION-DDR) CCTG-PR-25 NCT06439225.,,,,
418,Kaleido registry: A multi-center registry platform with site staff and automation to enable accelerated clinical research and drug development at scale in community practices.,,,,
419,Efficacy of immune checkpoint inhibitors (ICI) in patients (pts) with central nervous system (CNS) metastases (mets) from solid tumors: A systematic review and meta-analysis.,,,,
420,Progression-free survival as a surrogate outcome for overall survival in ovarian cancer maintenance therapy randomized controlled trials.,,,,
421,"Anxiety, depression, fear of cancer recurrence (FCR) and health-related quality of life (HRQL) in people with melanoma receiving adjuvant therapies.",,,,
422,Welcome and Introduction,,,,
423,The Power of Choice in a Cancer Journey,,,,
424,Spiritual Care and Religious Literacy in Cancer Care,,,,
425,Cancer Care Choices: What Patients Want and What Oncologists Wish,,,,
426,Breast Cancer Doesn't Care About Gender,,,,
427,Too Young for Cancer,,,,
428,Transforming the Battlefield: Targeting the Tumor Microenvironment,,,,
429,Deciphering and Disrupting Immunotherapy Resistance Pathways,,,,
430,Pushing the Boundaries: Next-Generation Immunotherapy Combinations,,,,
431,Panel Question and Answer,,,,
432,Artificial Intelligence in Cancer Care: How ASCO Is Influencing Artificial Intelligence in the Cancer Community,,,,
433,Practical Applications of Artificial Intelligence in the Practice Setting,,,,
434,Moderator,,,,
435,Translational Researcher Perspective,,,,
436,Medical Oncologist Perspective,,,,
437,Hematologist-Oncologist Perspective,,,,
438,Panel Question and Answer,,,,
439,Emerging Therapeutics for Patients with Brain Tumors and Rare Oncogenic Drivers,,,,
440,Targeted Therapy for Patients With IDH-Mutant Glioma,,,,
441,Selection of Blood-Brain Barrier Penetrant Inhibitors for Brain Metastases and Primary CNS Malignancies,,,,
442,Panel Question and Answer,,,,
443,Panel Question and Answer,,,,
444,Panel Question and Answer,,,,
445,Chair,,,,
446,Chair,,,,
447,Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients after allo-HSCT: A phase I trial.,Allogeneic Double-Negative T Cell,,,
448,"Engineering iPSC-derived mesenchymal stem cells (i MSCs) to secrete IL-7/IL-15 for modulation of the tumor microenvironment in a ""cold"" ovarian tumor model.",iPSC-Derived Mesenchymal Stem Cell,,,
449,Novel dynamic circulating biomarkers for predicting therapeutic efficacy of PRaG regimen in advanced refractory solid tumors.,PRaG,,,
450,Consolidative camrelizumab following definitive concurrent chemoradiotherapy with involved-field irradiation in locally advanced esophageal squamous cell carcinoma: A single-arm phase 2 trial.,Camrelizumab,,,
451,Neoadjuvant serplulimab with concurrent chemoradiotherapy in resectable esophagogastric junction adenocarcinoma: Phase 2 updated results.,Serplulimab,,,
452,A randomized controlled study of tislelizumab combined with concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer and the predictive value of T lymphocyte subsets for efficacy.,Tislelizumab,,,
453,"PD-1 inhibitors combined with radiotherapy and GM-CSF, sequentially followed by IL-2 regimen in advanced refractory solid tumors: A prospective, multicenter clinical trial.",IL-2,,,
454,Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA).,Autologous T Cell,,,
455,"A multi-center, single-arm, phase II study of pemigatinib combined with immune checkpoint inhibitor in FGFR1/2/3 alteration advanced solid tumor.",Pemigatinib,,,
456,Cardiovascular risks associated with aromatase inhibitors versus tamoxifen in breast cancer: A systematic review and meta-analysis.,Tamoxifen,,,
457,"BC3195, a novel ADC targeting cadherin-3 (CDH3): Updated results of a first-in-human phase I study in patients with advanced solid malignancies.",BC3195,,,
458,"RC48-ADC combined with radiotherapy and immunotherapy as salvage therapy for advanced solid tumors with HER2 expression: A multicenter, phase II trial.",RC48,,,
459,Phase 1 dose-escalation trial of talazoparib in combination with belinostat in select advanced solid tumors.,"Belinostat, Talazoparib",,,
460,Effect of irradiation on the killing effect of NK cells in colon cancer through MYB/TIM3 axis.,NK Cell,,,
461,The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: Preliminary results from a first-in-human phase 1/2 study.,ACE-86225106,,,
462,MODULE 4: Current Role of CAR T-Cell Therapy in Various Non-Hodgkin Lymphoma (NHL) Subtypes,CAR T Cell,,,
463,Role of Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM),CAR T Cell,,,
464,"PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.","Pembrolizumab, Ramucirumab",,,
465,"Envafolimab plus docetaxel in combination with or without trilaciclib versus docetaxel in pretreated advanced or metastatic non-small cell lung cancer (NSCLC): Preliminary analysis of an open-label, randomized, phase II trial.","Docetaxel, Envafolimab",Trilaciclib,Docetaxel,
466,Second-line treatment patterns and outcomes of advanced gastrointestinal stromal tumor: A real-world study.,,,,
467,Predicting transposable element-derived neoantigens in ATRX-mutated sarcoma.,,,,
468,Spatial and bulk transcriptomic analysis of skin Kaposi sarcoma lesions: Differences by disease characteristics.,,,,
469,Early assessment of response to chemotherapy via ctDNA in soft tissue sarcoma.,,,,
470,Kaposi sarcoma herpesvirus (KSHV) subtypes and impact on survival in 107 patients with Kaposi sarcoma and other KSHV-associated diseases.,,,,
471,Advancing precision oncology in soft tissue sarcomas: The role of iTRAC in metastatic risk stratification and treatment personalization.,,,,
472,Molecular subtyping and insights into sarcoma biology and prognosis.,,,,
473,Early on-treatment ctDNA dynamics and response by imaging in patients with sarcoma.,,,,
474,MicroRNA-based biomarkers of outcome in soft tissue sarcoma treated with hypofractionated preoperative radiation therapy.,,,,
475,Circulating free DNA derived from active chromatin as a predictive biomarker for clinical benefit to checkpoint inhibitor-based therapies in metastatic leiomyosarcoma.,,,,
476,Neutrophil-to-lymphocyte ratio as a clinical biomarker for immune checkpoint inhibitor response in advanced sarcoma.,,,,
477,Pediatric patients with tenosynovial giant cell tumor: Real-world results from an observational registry.,,,,
478,"Gamma secretase inhibitors and desmoid fibromatosis: Lessons from a real world, comprehensive genomic study of desmoids and CTNNB1/APC mutated soft tissue tumors.",,,,
479,"The global, regional, and national burden of soft tissue sarcomas and other extraosseous sarcomas, 1990-2021: A systematic analysis for the Global Burden of Disease study 2021.",,,,
480,Clinicopathologic features and outcomes of follicular dendritic cell sarcoma with or without Castleman disease: A large retrospective cohort analysis.,,,,
481,Molecular-genetic characteristics of soft tissue sarcomas associated with the development of chemotherapy resistance.,,,,
482,Clinical activity of immune checkpoint blockade in advanced perivascular epithelioid cell neoplasms (PEComas): A retrospective single center study.,,,,
483,Detecting hotspots of intra- and transchromosomal fusions in liposarcomas by RNA sequencing.,,,,
484,Treatment discontinuation in desmoid tumors: Factors associated with better outcomes after sorafenib discontinuation.,,,,
485,Heterogeneity in epithelioid hemangioendothelioma (EHE): Insights into common and organ-specific tumor pathways.,,,,
486,"An Open-Label Clinical Trial Of Rvu120 As Monotherapy And In Combination With Ruxolitinib In Patients With Intermediate Or High-Risk, Primary Or Secondary Myelofibrosis (Potami-61).",RVU-120,Ruxolitinib,,
487,"A Randomized, Multi-Center Study Of Carfilzomib, Lenalidomide And Dexamethasone (Krd) With Or Without Daratumumab (D) For The Treatment Of Patients With Newly Diagnosed Multiple Myeloma (Ndmm): The Advance Clinical Trial","Carfilzomib, Dexamethasone, Lenalidomide",Daratumumab,,
488,Hematological Improvement And Other Clinical Benefits Of Elritercept As Monotherapy And In Combination With Ruxolitinib In Participants With Myelofibrosis (Mf) From The Ongoing Phase 2 Restore Trial,Elritercept,Ruxolitinib,,
489,"Golcadomide (Golca), A Cereblon E3 Ligase Modulator (Celmod™) Agent, ± Rituximab (R) In Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl): Updated Phase 1/2 Study Results",Golcadomide,Rituximab,,
490,Circulating Tumour Dna-Directed Intervention With Epcoritamab Alone Or In Combination With Lenalidomide And Rituximab Is Feasible In The Early Post-Car-T Population At High Risk Of Relapse: Preliminary Data From Eplcart,Epcoritamab,"Lenalidomide, Rituximab",,
491,"Novel Zcr (Zanubrutinib, Chidamide, Rituximab) ± Chop Regimen Demonstrates Promising Efficacy In Frontline Treatment Of Double-Expressor Diffuse Large B-Cell Lymphoma(De-Dlbcl)","Chidamide, Rituximab, Zanubrutinib",CHOP,,
492,Orelabrutinib Combined With Ice Regimen With Or Without Rituximab (O-Ice±R) For Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Extranodal Involvement,"ICE, Orelabrutinib",Rituximab,,
493,Zr Study: A Prospective Phase Ii Clinical Trial Evaluating Zanubrutinib-Rituximab Induction Therapy With Or Without Autologous Stem Cell Transplantation In Treatment-Naïve Mantle Cell Lymphoma,"Rituximab, Zanubrutinib",Autologous Stem Cell,,
494,Minimal Residual Disease With Bendamustine-Rituximab With Or Without Acalabrutinib In Patients With Previously Untreated Mantle Cell Lymphoma: Results From The Phase 3 Echo Trial,"Bendamustine, Rituximab",Acalabrutinib,,
495,"A Prospective, Two-Arm, Phase Ii Study To Evaluate The Efficacy And Safety Of Orelabrutinib Plus Zuberitamab With Or Without Lenalidomide (Hilo) In Patients With Treatment-Naïve Marginal Zone Lymphoma","Orelabrutinib, Zuberitamab",Lenalidomide,,
496,"Carfilzomib, Pomalidomide, Dexamethasone With And Without Daratumumab In Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study In China","Carfilzomib, Dexamethasone, Pomalidomide",Daratumumab,,
497,"Efficacy Of Rituximab-Bendamustine With Or Without Acalabrutinib In Patients With Untreated, High-Risk Mantle Cell Lymphoma: An Analysis Of The Phase 3 Echo Trial","Bendamustine, Rituximab",Acalabrutinib,,
498,Impact Of Hypomethylating Agents +/- Venetoclax For The Management Of Acute Myeloid Leukemia And Myelodysplastic Patients Relapsing After Allogeneic Stem Cell Transplantation: A Subanalysis On 308 Patients Of The Gitmo Aml/Mds-Relapse Registry Study.,Allogeneic Stem Cell,Venetoclax,,
499,Clinical Outcomes Of Newly Diagnosed Pcnsl Treated With Rituximab-Methotrexate-Cytarabine With Or Without Ibrutinib: A Retrospective Study,"Cytarabine, Methotrexate, Rituximab",Ibrutinib,,
500,"Orelabrutinib, Rituximab, And Thiotepa (Ort) In Combination With Orwithout High-Dose Methotrexate In Untreated Primary Central Nervoussystem Lymphoma","Orelabrutinib, Rituximab, Thiotepa",Methotrexate,,
